Literature DB >> 3100940

Differential modification of striatal D1 dopamine receptors and effector moieties by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in vivo and in vitro.

E J Hess, G Battaglia, A B Norman, I Creese.   

Abstract

Both in vivo and in vitro treatments with the irreversible protein-modifying reagent, N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ), were used to investigate rat striatal D1 dopamine receptor/effector interactions. Peripherally administered EEDQ markedly reduced D1 dopamine receptor binding and D1 dopamine receptor-stimulated adenylate cyclase in a dose-dependent manner. However, EEDQ administered in vivo did not result in functional modification of either the guanine nucleotide-regulatory protein (Ns) or the catalytic subunit of striatal adenylate cyclase as assessed via guanine nucleotide- or forskolin-stimulated cAMP production. Interestingly, the loss in D1 dopamine receptor binding did not correlate directly with observed reductions in dopamine-stimulated adenylate cyclase activity; 40% of D1 dopamine receptor binding was lost with no significant reduction in the Vmax of dopamine-stimulated adenylate cyclase activity. Conversely, the reduction by EEDQ of the adenylate cyclase activity stimulated by the partial agonist SKF38393 was reduced in parallel with EEDQ-induced reductions in the D1 dopamine receptor Bmax. However, when SKF38393-stimulated adenylate cyclase activity was potentiated by forskolin, approximately 30% of receptors could be lost with no significant reduction in cAMP production, resembling the pattern observed utilizing the full agonist dopamine. In vivo pretreatment with the specific D1 antagonist, SCH23390, prevented reductions in dopamine-stimulated adenylate cyclase activity and D1 dopamine receptor binding, suggesting that EEDQ acts at the ligand recognition site of the receptor. Unlike in vivo treatment, in vitro EEDQ treatment resulted in dose-dependent decreases in catalytic subunit activity as assessed by forskolin-stimulated cAMP production, indicating that, in vitro, the adenylate cyclase catalytic subunit is vulnerable to EEDQ-induced modification. These data indicate that EEDQ is an effective tool for elucidating the mechanisms and biochemistry of D1 dopamine receptor/effector coupling.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3100940

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  7 in total

1.  Behavioral effects of dopamine receptor inactivation in the caudate-putamen of preweanling rats: role of the D2 receptor.

Authors:  Taleen Der-Ghazarian; Crystal B Widarma; Arnold Gutierrez; Leslie R Amodeo; Joseph M Valentine; Danielle E Humphrey; Ashley E Gonzalez; Cynthia A Crawford; Sanders A McDougall
Journal:  Psychopharmacology (Berl)       Date:  2013-09-22       Impact factor: 4.530

2.  Relationship between D1 dopamine receptors, adenylate cyclase, and the electrophysiological responses of rat nucleus accumbens neurons.

Authors:  P A Johansen; X T Hu; F J White
Journal:  J Neural Transm Gen Sect       Date:  1991

3.  Irreversible antagonism of 5HT2c receptors by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ).

Authors:  Y G Ni; N Camacho; R Miledi
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-18       Impact factor: 11.205

4.  Importance of D1 and D2 receptor stimulation for the induction and expression of cocaine-induced behavioral sensitization in preweanling rats.

Authors:  Sanders A McDougall; Krista N Rudberg; Ana Veliz; Janhavi M Dhargalkar; Aleesha S Garcia; Loveth C Romero; Ashley E Gonzalez; Alena Mohd-Yusof; Cynthia A Crawford
Journal:  Behav Brain Res       Date:  2017-03-08       Impact factor: 3.332

5.  Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset.

Authors:  K K Gnanalingham; D D Erol; A J Hunter; L A Smith; P Jenner; C D Marsden
Journal:  Psychopharmacology (Berl)       Date:  1995-02       Impact factor: 4.530

6.  The differential behavioural effects of benzazepine D1 dopamine agonists with varying efficacies, co-administered with quinpirole in primate and rodent models of Parkinson's disease.

Authors:  K K Gnanalingham; A J Hunter; P Jenner; C D Marsden
Journal:  Psychopharmacology (Berl)       Date:  1995-02       Impact factor: 4.530

7.  Identification of a specific assembly of the g protein golf as a critical and regulated module of dopamine and adenosine-activated cAMP pathways in the striatum.

Authors:  Denis Hervé
Journal:  Front Neuroanat       Date:  2011-08-05       Impact factor: 3.856

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.